A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Withdrawn · NCT04635111
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor
At a glance
- Research payments reported, 2025
- $11,714
- U.S. investigators named
- 2
- Sites paid
- 3
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- TURALIO™ (drug)
- Dates
- Started 2021-01-07; completion 2026-07-24
- Results posted
- Not yet
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $11,714 in research payments for this study in 2025 (8 payments).
Products named: Turalio
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Arun S. Singh, M.D. Hematology & Oncology · Santa Monica, CA
- Gabriel R. Tinoco Suarez, M.D. Medical Oncology · Columbus, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ohio State University $6,678
- Ronald Reagan UCLA Medical Center, CA $5,000
- Arthur G James Cancer Hospital $36
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.